aldafermin

NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data
Xconomy
Tue, 02/25/20 - 12:04 am
NGM Biopharmaceuticals
NASH
clinical trials
aldafermin